

**BIOCON GROUP**

**FACT SHEET**

**December - 2024**

<b>BIOCON LIMITED (CONSOLIDATED)</b>			
<b>PROFIT &amp; LOSS STATEMENT</b>			
(Rs. Crores)			
<b>Particulars</b>	<b>Q3 FY 25</b>	<b>Q3 FY 24</b>	<b>Variance %</b>
<b><u>INCOME</u></b>			
Generics	686	703	-2%
Biosimilars	2,289	2,483	-8%
Research services	944	854	11%
Inter-segment	(98)	(86)	13%
<b>Revenue from operations #</b>	<b>3,821</b>	<b>3,954</b>	<b>-3%</b>
Other income	35	566	-94%
<b>TOTAL REVENUE</b>	<b>3,856</b>	<b>4,519</b>	<b>-15%</b>
<b><u>EXPENDITURE</u></b>			
Material & Power costs	1,454	1,320	10%
Staff costs	731	555	32%
Research & Development expenses*	199	329	-40%
Other expenses	686	823	-17%
<b>Manufacturing, staff &amp; other expenses</b>	<b>3,070</b>	<b>3,027</b>	<b>1%</b>
<b>EBITDA</b>	<b>787</b>	<b>1,492</b>	<b>-47%</b>
Interest & Finance charges	223	267	-16%
Depreciation & Amortisation	425	415	3%
Share of loss / (profit) in JV / Associate, net	-	24	-100%
<b>PBT BEFORE EXCEPTIONAL ITEM</b>	<b>138</b>	<b>787</b>	<b>-82%</b>
Exceptional item	18	21	-15%
<b>PBT</b>	<b>156</b>	<b>808</b>	<b>-81%</b>
Taxes	72	53	37%
Taxes on exceptional item	3	2	130%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>81</b>	<b>753</b>	<b>-89%</b>
Minority interest	53	90	-41%
Minority interest on exceptional item	3	3	100%
<b>NET PROFIT FOR THE PERIOD</b>	<b>25</b>	<b>660</b>	<b>-96%</b>
<b>EPS Rs.</b>	<b>0.2</b>	<b>5.5</b>	
<b>NET PROFIT BEFORE EXCEPTIONAL ITEM</b>			
	<b>13</b>	<b>644</b>	<b>-98%</b>
Exceptional item, net of taxes	12	16	
<b>NET PROFIT FOR THE PERIOD</b>	<b>25</b>	<b>660</b>	<b>-96%</b>
<i># Licensing Income</i>	7	5	
<i>* Gross Research &amp; Development expenses</i>	199	332	

BIOCON LIMITED (CONSOLIDATED)			(Rs. Crores)
PROFIT & LOSS STATEMENT			
Particulars	Q3 FY 25	Q2 FY 25	Variance %
<b>INCOME</b>			
Generics	686	624	10%
Biosimilars	2,289	2,182	5%
Research services	944	891	6%
Inter-segment	(98)	(107)	-8%
<b>Revenue from operations #</b>	<b>3,821</b>	<b>3,590</b>	<b>6%</b>
Other income	35	33	7%
<b>TOTAL REVENUE</b>	<b>3,856</b>	<b>3,623</b>	<b>6%</b>
<b>EXPENDITURE</b>			
Material & Power costs	1,454	1,279	14%
Staff costs	731	746	-2%
Research & Development expenses*	199	200	0%
Other expenses	686	679	1%
<b>Manufacturing, staff &amp; other expenses</b>	<b>3,070</b>	<b>2,905</b>	<b>6%</b>
<b>EBITDA</b>	<b>787</b>	<b>718</b>	<b>10%</b>
Interest & Finance charges	223	226	-1%
Depreciation & Amortisation	425	420	1%
<b>PBT BEFORE EXCEPTIONAL ITEM</b>	<b>138</b>	<b>72</b>	<b>91%</b>
Exceptional item, Net	18	26	-100%
<b>PBT</b>	<b>156</b>	<b>98</b>	<b>59%</b>
Taxes	72	47	51%
Taxes on exceptional item	3	4	-25%
Deferred tax charge on withdrawal of indexation benefit	-	20	100%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>81</b>	<b>27</b>	<b>201%</b>
Minority interest	53	38	38%
Minority interest on exceptional item	3	5	-
<b>NET PROFIT FOR THE PERIOD</b>	<b>25</b>	<b>(16)</b>	<b>-256%</b>
<b>EPS Rs.</b>	<b>0.2</b>	<b>(0.1)</b>	
<b>NET PROFIT BEFORE EXCEPTIONAL ITEM</b>			
	13	(13)	-198%
Exceptional item	12	(3)	
<b>NET PROFIT FOR THE PERIOD</b>	<b>25</b>	<b>(16)</b>	<b>-256%</b>
# Licensing Income	7	13	
* Gross Research & Development expenses	199	200	

BIOCON LIMITED (CONSOLIDATED)			(Rs. Crores)
PROFIT & LOSS STATEMENT			
Particulars	9M FY 25	9M FY24	Variance %
<b>INCOME</b>			
Generics	1,970	2,080	-5%
Biosimilars	6,554	6,466	1%
Research services	2,624	2,572	2%
Inter-segment	(304)	(280)	9%
<b>Revenue from operations #</b>	<b>10,845</b>	<b>10,839</b>	<b>0%</b>
Other income	1,171	817	43%
<b>TOTAL REVENUE</b>	<b>12,016</b>	<b>11,656</b>	<b>3%</b>
<b>EXPENDITURE</b>			
Material & Power costs	4,009	3,870	4%
Staff costs	2,180	1,605	36%
Research & Development expenses*	627	908	-31%
Other expenses	1,941	2,073	-6%
<b>Manufacturing, staff &amp; other expenses</b>	<b>8,757</b>	<b>8,456</b>	<b>4%</b>
<b>EBITDA</b>	<b>3,260</b>	<b>3,200</b>	<b>2%</b>
Interest & Finance charges	685	747	-8%
Depreciation & Amortisation	1,251	1,162	8%
Share of loss / (profit) in JV / Associate, net	-	82	100%
<b>PBT BEFORE EXCEPTIONAL ITEM</b>	<b>1,324</b>	<b>1,209</b>	<b>9%</b>
Exceptional item, Net	76	(3)	-
<b>PBT</b>	<b>1,400</b>	<b>1,206</b>	<b>16%</b>
Taxes	392	133	194%
Taxes on exceptional item	18	(2)	-
Deferred tax charge on withdrawal of indexation benefit	20	-	0%
<b>NET PROFIT BEFORE MINORITY INTEREST</b>	<b>970</b>	<b>1,075</b>	<b>-10%</b>
Minority interest	284	189	50%
Minority interest on exceptional item	17	(1)	-
<b>NET PROFIT FOR THE PERIOD</b>	<b>669</b>	<b>887</b>	<b>-25%</b>
<b>EPS Rs.</b>	<b>5.6</b>	<b>7.4</b>	
<b>NET PROFIT BEFORE EXCEPTIONAL ITEM</b>			
	648	887	-27%
Exceptional item, net of taxes	21	(0)	
<b>NET PROFIT FOR THE PERIOD</b>	<b>669</b>	<b>887</b>	<b>-25%</b>
<i># Licensing Income</i>	26	178	
<i>* Gross Research &amp; Development expenses</i>	627	934	

**BIOCON LIMITED (CONSOLIDATED)**  
**BALANCE SHEET**

(Rs Crores)

Particulars	Dec 31, 2024	Mar 31, 2024
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Property, plant and equipment	7,369	7,418
(b) Capital work-in-progress	4,798	3,985
(c) Right-of-use assets	618	575
(d) Goodwill	16,815	16,372
(e) Other intangible assets	6,004	6,279
(f) Intangible assets under development	4,363	4,008
(g) Financial assets		
Investments	897	684
Derivative assets	174	266
Other financial assets	66	147
(h) Income tax asset, net	461	413
(i) Deferred tax asset, net	260	317
(j) Other non-current assets	537	428
<b>Non-current assets</b>	<b>42,362</b>	<b>40,892</b>
<b>Current assets</b>		
(a) Inventories	5,052	4,944
(b) Financial assets		
Investments	549	316
Trade receivables	6,365	6,231
Cash and cash equivalents	1,765	1,234
Other bank balances	804	1,025
Derivative assets	103	138
Other financial assets	285	577
(c) Other current assets	728	715
<b>Current assets</b>	<b>15,651</b>	<b>15,180</b>
<b>TOTAL - ASSETS</b>	<b>58,013</b>	<b>56,072</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity share capital	600	600
(b) Other equity	21,023	19,183
<b>Equity attributable to owners of the Company</b>	<b>21,623</b>	<b>19,783</b>
Non-controlling interests	5,942	5,491
<b>Total Equity</b>	<b>27,565</b>	<b>25,274</b>
<b>Non-current liabilities</b>		
(a) Financial liabilities		
Borrowings	14,186	12,932
Lease liabilities	521	492
Derivative liabilities	9	-
Other financial liabilities	1,736	1,073
(b) Other non-current liabilities	294	311
(c) Provisions	254	238
(d) Deferred tax liability, net	361	392
<b>Non-current liabilities</b>	<b>17,361</b>	<b>15,438</b>
<b>Current liabilities</b>		
(a) Financial liabilities		
Borrowings	3,152	2,797
Lease liabilities	94	55
Trade payables	6,559	6,272
Derivative liabilities	48	1
Other financial liabilities	2,254	5,001
(b) Other current liabilities	450	777
(c) Provisions	215	180
(d) Income tax liability, net	315	277
<b>Current liabilities</b>	<b>13,087</b>	<b>15,360</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>58,013</b>	<b>56,072</b>